Neuronetics, Inc. (NASDAQ:STIM) Stake Lessened by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP cut its stake in Neuronetics, Inc. (NASDAQ:STIM) by 12.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 128,069 shares of the company’s stock after selling 18,936 shares during the period. Dimensional Fund Advisors LP owned approximately 0.43% of Neuronetics worth $231,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in STIM. Acadian Asset Management LLC boosted its holdings in shares of Neuronetics by 23.7% in the second quarter. Acadian Asset Management LLC now owns 326,975 shares of the company’s stock valued at $587,000 after acquiring an additional 62,628 shares in the last quarter. Assenagon Asset Management S.A. boosted its holdings in shares of Neuronetics by 63.0% in the second quarter. Assenagon Asset Management S.A. now owns 135,746 shares of the company’s stock valued at $244,000 after acquiring an additional 52,450 shares in the last quarter. Silvercrest Asset Management Group LLC boosted its holdings in shares of Neuronetics by 4.6% in the first quarter. Silvercrest Asset Management Group LLC now owns 1,178,365 shares of the company’s stock valued at $5,609,000 after acquiring an additional 51,881 shares in the last quarter. Dorsey & Whitney Trust CO LLC boosted its holdings in shares of Neuronetics by 97.1% in the second quarter. Dorsey & Whitney Trust CO LLC now owns 95,880 shares of the company’s stock valued at $173,000 after acquiring an additional 47,228 shares in the last quarter. Finally, FourWorld Capital Management LLC bought a new position in shares of Neuronetics in the first quarter valued at approximately $171,000. 53.59% of the stock is currently owned by institutional investors.

Neuronetics Stock Down 2.2 %

Shares of NASDAQ:STIM opened at $0.89 on Tuesday. The company has a debt-to-equity ratio of 2.38, a quick ratio of 2.37 and a current ratio of 2.58. The company has a market cap of $26.70 million, a PE ratio of -0.93 and a beta of 2.27. Neuronetics, Inc. has a 52 week low of $0.66 and a 52 week high of $5.07. The firm has a 50 day simple moving average of $0.94 and a 200 day simple moving average of $2.01.

Neuronetics (NASDAQ:STIM) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.06). The business had revenue of $16.45 million for the quarter, compared to analysts’ expectations of $18.76 million. Neuronetics had a negative net margin of 45.06% and a negative return on equity of 109.00%. During the same quarter in the prior year, the firm posted ($0.17) EPS. As a group, research analysts expect that Neuronetics, Inc. will post -0.87 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts recently weighed in on STIM shares. William Blair restated a “market perform” rating on shares of Neuronetics in a report on Monday, August 12th. JMP Securities reduced their target price on shares of Neuronetics from $7.00 to $3.00 and set a “market outperform” rating for the company in a report on Wednesday, August 14th. Finally, Canaccord Genuity Group reduced their target price on shares of Neuronetics from $6.00 to $3.00 and set a “buy” rating for the company in a report on Tuesday, August 13th.

Insiders Place Their Bets

In related news, Director Robert Cascella bought 100,000 shares of the firm’s stock in a transaction on Thursday, September 12th. The stock was bought at an average price of $0.75 per share, with a total value of $75,000.00. Following the purchase, the director now directly owns 453,098 shares of the company’s stock, valued at approximately $339,823.50. This represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, Director Robert Cascella acquired 100,000 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The stock was acquired at an average cost of $0.75 per share, for a total transaction of $75,000.00. Following the completion of the acquisition, the director now owns 453,098 shares in the company, valued at approximately $339,823.50. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Keith J. Sullivan sold 24,162 shares of the business’s stock in a transaction dated Thursday, July 18th. The shares were sold at an average price of $1.90, for a total value of $45,907.80. Following the completion of the transaction, the chief executive officer now owns 1,324,354 shares in the company, valued at $2,516,272.60. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders purchased 211,776 shares of company stock worth $175,170 and sold 27,071 shares worth $48,293. Insiders own 9.80% of the company’s stock.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.